Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
Renal cancer PDO
Compare targeted and immune-related treatment conditions in renal cancer PDOs using apoptosis and immune-cell readouts.
H&EAnnexin V/PICD3CD8
Model source
Patient renal tumor tissue
Culture / format
PDO · Immune co-culture study format
Available study data
TRiCBIO renal cancer PDO study data
Model characterization
Renal PDO identity, apoptosis and immune readouts
Source-tissue and PDO histology show renal model morphology. Annexin V/PI and CD3/CD8 flow plots from the same project compare apoptosis and immune-cell changes across treatment conditions.
View imageModel confirmation: source tissue, PDO histology and bright-field views establish the model context before treatment studies.
TRiCBIO RCC PDO 2.0 study data
View imageCell-death analysis: Annexin V/PI flow plots compare cell distributions after control, targeted, immune and combination treatments.
TRiCBIO RCC PDO 2.0 study data
Immune readouts: CD3/CD8 flow cytometry is interpreted with apoptosis measurements to compare cell-death and immune changes across the same treatment conditions.
TRiCBIO RCC PDO 2.0 study dataView the complete study figure set
View imageStudy planning
Models and assays for your study
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Integrate renal-tumor identity, apoptosis and immune change
Renal cancer programs may span targeted agents, mTOR-associated regimens and immunotherapy. Establish source-tissue and PDO identity before comparing treatment conditions with consistent controls, apoptosis and immune readouts.
Review pathology and sample context
Confirm renal cancer pathology, sampling site, prior treatment, sample state and available source-tissue records.
Confirm identity and study QC
Compare source-tissue H&E, PDO bright-field and PDO H&E, adding study-relevant markers such as PAX8 and CD10 before treatment studies.
Design conditions around mechanism
Set dose, timing, single-agent groups and controls around targeted, mTOR-associated, ICB or combination mechanisms, then compare results using consistent analysis criteria.
Interpret apoptosis and immune results together
Integrate Annexin V/PI, CD3/CD8/CD107a flow, histology and viability to distinguish tumor-cell death, immune-population shifts and sample variation.
Research applications
Recommended applications
- Targeted and mTOR-related regimens
- ICB studies
- Apoptosis and immune-cell changes
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
H&EAnnexin V/PICD3CD8
Available assays
- Annexin V
- IHC / IF
- Flow cytometry
- Viability
QC approach
QC combines tissue identity, morphology, apoptosis and immune functional readouts.
Study & delivery
Model characterization, treatment data and reporting
Choose a supplied model or a TRiCBIO-run intervention study. Typical deliverables include functional data and a project report.
Study design
Drug panels and immune co-culture conditions are configured around sample state, target and study objective.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a renal cancer PDO study
Tell us about the tumor type, samples, candidate and results you want to compare. Our scientists will help plan your renal cancer PDO study.